A detailed history of Point72 Hong Kong LTD transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Point72 Hong Kong LTD holds 3,100 shares of RCUS stock, worth $48,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,100
Holding current value
$48,980
% of portfolio
0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.69 - $18.01 $42,439 - $55,831
3,100 New
3,100 $47,000
Q2 2022

Aug 15, 2022

SELL
$17.23 - $37.73 $133,946 - $293,313
-7,774 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$28.92 - $41.83 $211,839 - $306,404
7,325 Added 1631.4%
7,774 $245,000
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $14,089 - $21,763
449 New
449 $18,000
Q2 2021

Aug 16, 2021

SELL
$22.75 - $35.77 $27,345 - $42,995
-1,202 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$26.16 - $41.39 $31,444 - $49,750
1,202 New
1,202 $34,000
Q3 2020

Nov 16, 2020

SELL
$17.14 - $25.47 $212,638 - $315,980
-12,406 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$13.97 - $36.56 $173,311 - $453,563
12,406 New
12,406 $307,000
Q2 2018

Aug 14, 2018

SELL
$12.24 - $17.05 $93,709 - $130,534
-7,656 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$15.44 - $17.71 $118,208 - $135,587
7,656 New
7,656 $118,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.